시장보고서

상품코드

1671181

당뇨병 치료제 시장 규모, 점유율, 동향, 업계 분석 : 유형별, 약제 클래스별, 투여 경로별, 유통 채널별, 지역별 - 예측(2025-2034년)

Diabetes Drug Market Size, Share, Trends, Industry Analysis Report: By Type, Drug Class, Route of Administration, Distribution Channel, and Region - Market Forecast, 2025-2034

발행일: 2025년 02월 | 리서치사:

Polaris Market Research | 페이지 정보: 영문 117 Pages | 배송안내 : 1-2일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 조사에 따르면 당뇨병 치료제 시장 규모는 2034년까지 1,637억 9,000만 달러에 달할 전망입니다. 이 리포트에서는 현재 시장 역학의 상세 인사이트와 향후 시장 성장에 관한 분석을 제공하고 있습니다.

당뇨병 치료제 시장의 성장은 인구 고령화, 좌식 생활습관, 비만율 증가 등의 요인으로 인한 당뇨병, 특히 2형 당뇨병의 전 세계 유병률 증가에 기인합니다. 주요 촉진요인으로는 약물 제제의 발전, GLP-1 수용체 작용제 및 SGLT-2 억제제와 같은 새로운 치료제의 도입, 심혈관 질환 및 신장 합병증과 같은 동반 질환 관리에 대한 관심 증가 등을 들 수 있습니다. 당뇨병 치료제 시장 개발은 당뇨병 유병률이 증가하고 있는 신흥 국가 시장과 병용요법 및 맞춤의료 개발에서 비즈니스 기회가 존재합니다.

시장에 영향을 미치는 주요 동향으로는 더 나은 질병 관리를 위한 디지털 헬스 기술 채택, 바이오시밀러 사용 증가, 비침습적 치료의 중요성 등이 있습니다. 전반적으로 효과적이고 편리한 당뇨병 관리 솔루션에 대한 수요 증가에 대응하기 위해 의료 시스템이 진화함에 따라 시장은 계속 확대될 것으로 예상됩니다.

당뇨병 치료제 시장 : 분석 개요

유형별로는 2형 당뇨병이 당뇨병 치료제 시장 매출에서 큰 비중을 차지하고 있으며, 비만율 증가와 고령화로 인해 높은 성장세를 보이고 있습니다. 이 부문은 인슐린 요법과 인슐린 전달 시스템의 발전에 힘입어 지속적으로 성장하고 있습니다.

투여 경로별로는 경구 투여 부문이 당뇨병 치료제 시장, 특히 메트포르민과 SGLT-2 억제제와 같은 약물의 편의성과 폭넓은 수용성으로 인해 당뇨병 치료제 시장 점유율을 독점하고 있습니다. 정맥 투여 부문은 시장 점유율이 가장 작지만, 특히 인슐린 펌프의 사용과 병원에서의 전문적인 치료로 인해 꾸준히 성장하고 있습니다.

약제군별로는 인슐린 제제가 특히 1형 당뇨병 치료에서 여전히 우위를 유지하고 있지만, SGLT-2 억제제는 특히 2형 당뇨병 관리에서 심혈관 보호 및 신장 보호의 다른 이점에 힘입어 가장 빠르게 성장하고 있습니다.

북미는 높은 당뇨병 유병률과 첨단화된 의료 인프라에 힘입어 가장 큰 시장 점유율을 차지하고 있습니다. 반면, 아시아태평양은 당뇨병 환자 증가와 의료 접근성 향상에 힘입어 가장 빠르게 성장하고 있는 지역입니다.

당뇨병 치료제 시장의 주요 기업에는 Novo Nordisk, Sanofi, Eli Lilly, Merck, Boehringer Ingelheim이 포함됩니다. 이들 기업은 인슐린 치료제, GLP-1 수용체 작용제, SGLT-2 억제제 등 다양한 당뇨병 치료제의 개발, 제조, 판매에 적극적으로 참여하고 있습니다.

시장 스냅숏
당뇨병 치료제 시장 역학
- 촉진요인과 기회
  - GLP-1 수용체 작용제의 채택 증가
  - 맞춤형 당뇨병 치료로의 이동
- 억제요인과 과제
  - 당뇨병 치료제의 고비용
PESTLE 분석
당뇨병 치료제 시장 동향
밸류체인 분석
COVID-19의 영향 분석

제5장 세계의 당뇨병 치료제 시장 : 유형별

주요 분석 결과
서론
1형
2형

제6장 세계의 당뇨병 치료제 시장 : 투여 경로별

주요 분석 결과
서론
경구
정맥내

제7장 세계의 당뇨병 치료제 시장 : 약제 클래스별

주요 조사 결과
서론
인슐린
감작제(Sensitizers)
SGLT-2 저해제
알파 글루코시다아제 저해제

제8장 세계의 당뇨병 치료제 시장 : 최종사용자별

주요 분석 결과
서론
병원·클리닉
외래 클리닉

제9장 세계의 당뇨병 치료제 시장 : 지역별

주요 분석 결과
서론
- 당뇨병 치료제 시장 평가 : 지역별(2020-2034년)
북미
- 북미 : 유형별(2020-2034년)
- 북미 : 투여 경로별(2020-2034년)
- 북미 : 약제 클래스별(2020-2034년)
- 북미 : 최종사용자별(2020-2034년)
- 미국
- 캐나다
유럽
- 유럽 : 유형별(2020-2034년)
- 유럽 : 투여 경로별(2020-2034년)
- 유럽 : 약제 클래스별(2020-2034년)
- 유럽 : 최종사용자별(2020-2034년)
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
아시아태평양
- 아시아태평양 : 유형별(2020-2034년)
- 아시아태평양 : 투여 경로별(2020-2034년)
- 아시아태평양 : 약제 클래스별(2020-2034년)
- 아시아태평양 : 최종사용자별(2020-2034년)
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
중동 및 아프리카
- 중동 및 아프리카 : 유형별(2020-2034년)
- 중동 및 아프리카 : 투여 경로별(2020-2034년)
- 중동 및 아프리카 : 약제 클래스별(2020-2034년)
- 중동 및 아프리카 : 최종사용자별(2020-2034년)
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
라틴아메리카
- 라틴아메리카 : 유형별(2020-2034년)
- 라틴아메리카 : 투여 경로별(2020-2034년)
- 라틴아메리카 : 약제 클래스별(2020-2034년)
- 라틴아메리카 : 최종사용자별(2020-2034년)
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카

제10장 경쟁 구도

사업 확대·기업 인수 분석
- 사업 확대
- 기업 인수
제휴/협업/합의/공개

제11장 기업 개요

Novo Nordisk
Sanofi
Eli Lilly
Merck
Boehringer Ingelheim
AstraZeneca
Johnson & Johnson
Novartis
Bayer
GlaxoSmithKline

KSA 25.04.02

The diabetes drug market size is expected to reach USD 163.79 billion by 2034, according to a new study by Polaris Market Research. The report "Diabetes Drug Market Size, Share, Trends, Industry Analysis Report: By Type (Type 1 and Type 2), Drug Class, Route of Administration, Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The diabetes drug market growth is attributed to the rising global prevalence of diabetes, particularly type 2 diabetes, due to factors such as aging populations, sedentary lifestyles, and increasing obesity rates. Key drivers include advancements in drug formulations, the introduction of new therapies such as GLP-1 receptor agonists and SGLT-2 inhibitors, and an increasing focus on managing comorbidities such as cardiovascular disease and renal complications. Diabetes drug market opportunities exist in emerging markets where the prevalence of diabetes is rising, as well as in the development of combination therapies and personalized medicine.

Key trends influencing the market include the adoption of digital health technologies for better disease management, the rise in use of biosimilars, and an emphasis on noninvasive treatments. Overall, the market is expected to continue expanding as healthcare systems evolve to address the growing demand for effective and convenient diabetes management solutions.

Diabetes Drug Market Report Highlights

Based on type, the type-2 diabetes holds a larger share of the diabetes drug market revenue and is experiencing a higher growth, driven by rising obesity rates and an aging population. The segment continues to grow, supported by advancements in insulin therapies and insulin delivery systems.

The oral administration segment, based on route of administration, dominates the diabetes drug market share due to its convenience and wide acceptance, particularly with drugs such as metformin and SGLT-2 inhibitors. The intravenous segment, while holding the smallest market share, is growing steadily, particularly due to the use of insulin pumps and specialized treatments in hospitals.

Based on drug class, the insulin segment remains the dominant segment, especially in type-1 diabetes treatment, but SGLT-2 inhibitors is the fastest-growing segment, driven by their additional benefits in cardiovascular and renal protection, especially in type-2 diabetes management.

North America holds the largest market share, driven by high diabetes prevalence and advanced healthcare infrastructure, whereas Asia Pacific is the fastest-growing region, fueled by rising diabetes cases and improving healthcare access.

A few key players in the diabetes drug market include major pharmaceutical companies such as Novo Nordisk, Sanofi, Eli Lilly, Merck, and Boehringer Ingelheim. These companies are actively involved in the development, production, and distribution of a wide range of diabetes treatments, including insulin therapies, GLP-1 receptor agonists, and SGLT-2 inhibitors.

Polaris Market Research has segmented the diabetes drug market report on the basis of type, route of administration, drug class, distribution channel, and region:

By Type Outlook (Revenue - USD Billion, 2020-2034)

Type-1
Type-2

By Administration Outlook (Revenue - USD Billion, 2020-2034)

Oral
Intravenous
Subcutaneous

By Drug Class Outlook (Revenue - USD Billion, 2020-2034)

Insulin
Sensitizers
SGLT-2 Inhibitors
Alpha-Glucosidase Inhibitors
Others
By Distribution Channel (Revenue - USD Billion, 2020-2034)
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies

By Regional Outlook (Revenue - USD Billion, 2020-2034)

North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Global Diabetes Drugs Market Insights

4.1. Diabetes Drugs Market - Market Snapshot
4.2. Diabetes Drugs Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Increasing Adoption of GLP-1 Receptor Agonists
  - 4.2.1.2. Shift Towards Personalized Diabetes Treatments
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. High Cost of Diabetes Medications
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Diabetes Drugs Market Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Diabetes Drugs Market, by Type

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
5.3. Type-1
- 5.3.1. Global Diabetes Drugs Market, by Type-1, by Region, 2020-2034 (USD Billion)
5.4. Type-2
- 5.4.1. Global Diabetes Drugs Market, by Type-2, by Region, 2020-2034 (USD Billion)

6. Global Diabetes Drugs Market, by Administration

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
6.3. Oral
- 6.3.1. Global Diabetes Drugs Market, by Oral, by Region, 2020-2034 (USD Billion)
6.4. Intravenous
- 6.4.1. Global Diabetes Drugs Market, by Intravenous, by Region, 2020-2034 (USD Billion)

7. Global Diabetes Drugs Market, by Drug Class

7.1. Key Findings
7.2. Introduction
- 7.2.1. Global Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
7.3. Insulin
- 7.3.1. Global Diabetes Drugs Market, by Insulin, by Region, 2020-2034 (USD Billion)
7.4. Sensitizers
- 7.4.1. Global Diabetes Drugs Market, by Sensitizers, by Region, 2020-2034 (USD Billion)
7.5. SGLT-2 Inhibitors
- 7.5.1. Global Diabetes Drugs Market, by SGLT-2 Inhibitors, by Region, 2020-2034 (USD Billion)
7.6. Alpha-Glucosidase Inhibitors
- 7.6.1. Global Diabetes Drugs Market, by Alpha-Glucosidase Inhibitors, by Region, 2020-2034 (USD Billion)

8. Global Diabetes Drugs Market, by End Users

8.1. Key Findings
8.2. Introduction
- 8.2.1. Global Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
8.3. Hospital & Clinics
- 8.3.1. Global Diabetes Drugs Market, by Hospital & Clinics, by Region, 2020-2034 (USD Billion)
8.4. Ambulatory Clinics
- 8.4.1. Global Diabetes Drugs Market, by Ambulatory Clinics, by Region, 2020-2034 (USD Billion)

9. Global Diabetes Drugs Market, by Geography

9.1. Key Findings
9.2. Introduction
- 9.2.1. Diabetes Drugs Market Assessment, By Geography, 2020-2034 (USD Billion)
9.3. Diabetes Drugs Market - North America
- 9.3.1. North America: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.3.2. North America: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
- 9.3.3. North America: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
- 9.3.4. North America: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
- 9.3.5. Diabetes Drugs Market - US
  - 9.3.5.1. US: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  - 9.3.5.2. US: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  - 9.3.5.3. US: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  - 9.3.5.4. US: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
- 9.3.6. Diabetes Drugs Market - Canada
  - 9.3.6.1. Canada: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  - 9.3.6.2. Canada: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  - 9.3.6.3. Canada: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  - 9.3.6.4. Canada: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
9.4. Diabetes Drugs Market - Europe
- 9.4.1. Europe: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.4.2. Europe: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
- 9.4.3. Europe: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
- 9.4.4. Europe: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
- 9.4.5. Diabetes Drugs Market - UK
  - 9.4.5.1. UK: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  - 9.4.5.2. UK: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  - 9.4.5.3. UK: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  - 9.4.5.4. UK: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
- 9.4.6. Diabetes Drugs Market - France
  - 9.4.6.1. France: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  - 9.4.6.2. France: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  - 9.4.6.3. France: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  - 9.4.6.4. France: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
- 9.4.7. Diabetes Drugs Market - Germany
  - 9.4.7.1. Germany: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  - 9.4.7.2. Germany: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  - 9.4.7.3. Germany: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  - 9.4.7.4. Germany: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
- 9.4.8. Diabetes Drugs Market - Italy
  - 9.4.8.1. Italy: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  - 9.4.8.2. Italy: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  - 9.4.8.3. Italy: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  - 9.4.8.4. Italy: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
- 9.4.9. Diabetes Drugs Market - Spain
  - 9.4.9.1. Spain: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  - 9.4.9.2. Spain: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  - 9.4.9.3. Spain: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  - 9.4.9.4. Spain: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
- 9.4.10. Diabetes Drugs Market - Netherlands
  - 9.4.10.1. Netherlands: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  - 9.4.10.2. Netherlands: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  - 9.4.10.3. Netherlands: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  - 9.4.10.4. Netherlands: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
- 9.4.11. Diabetes Drugs Market - Russia
  - 9.4.11.1. Russia: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  - 9.4.11.2. Russia: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  - 9.4.11.3. Russia: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  - 9.4.11.4. Russia: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
- 9.4.12. Diabetes Drugs Market - Rest of Europe
  - 9.4.12.1. Rest of Europe: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  - 9.4.12.2. Rest of Europe: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  - 9.4.12.3. Rest of Europe: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  - 9.4.12.4. Rest of Europe: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
9.5. Diabetes Drugs Market - Asia Pacific
- 9.5.1. Asia Pacific: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.5.2. Asia Pacific: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
- 9.5.3. Asia Pacific: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
- 9.5.4. Asia Pacific: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
- 9.5.5. Diabetes Drugs Market - China
  - 9.5.5.1. China: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  - 9.5.5.2. China: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  - 9.5.5.3. China: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  - 9.5.5.4. China: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
- 9.5.6. Diabetes Drugs Market - India
  - 9.5.6.1. India: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  - 9.5.6.2. India: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  - 9.5.6.3. India: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  - 9.5.6.4. India: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
- 9.5.7. Diabetes Drugs Market - Malaysia
  - 9.5.7.1. Malaysia: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  - 9.5.7.2. Malaysia: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  - 9.5.7.3. Malaysia: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  - 9.5.7.4. Malaysia: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
- 9.5.8. Diabetes Drugs Market - Japan
  - 9.5.8.1. Japan: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  - 9.5.8.2. Japan: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  - 9.5.8.3. Japan: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  - 9.5.8.4. Japan: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
- 9.5.9. Diabetes Drugs Market - Indonesia
  - 9.5.9.1. Indonesia: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  - 9.5.9.2. Indonesia: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  - 9.5.9.3. Indonesia: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  - 9.5.9.4. Indonesia: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
- 9.5.10. Diabetes Drugs Market - South Korea
  - 9.5.10.1. South Korea: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  - 9.5.10.2. South Korea: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  - 9.5.10.3. South Korea: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  - 9.5.10.4. South Korea: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
- 9.5.11. Diabetes Drugs Market - Australia
  - 9.5.11.1. Australia: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  - 9.5.11.2. Australia: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  - 9.5.11.3. Australia: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  - 9.5.11.4. Australia: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
- 9.5.12. Diabetes Drugs Market - Rest of Asia Pacific
  - 9.5.12.1. Rest of Asia Pacific: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  - 9.5.12.2. Rest of Asia Pacific: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  - 9.5.12.3. Rest of Asia Pacific: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  - 9.5.12.4. Rest of Asia Pacific: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
9.6. Diabetes Drugs Market - Middle East & Africa
- 9.6.1. Middle East & Africa: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.6.2. Middle East & Africa: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
- 9.6.3. Middle East & Africa: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
- 9.6.4. Middle East & Africa: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
- 9.6.5. Diabetes Drugs Market - Saudi Arabia
  - 9.6.5.1. Saudi Arabia: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  - 9.6.5.2. Saudi Arabia: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  - 9.6.5.3. Saudi Arabia: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  - 9.6.5.4. Saudi Arabia: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
- 9.6.6. Diabetes Drugs Market - UAE
  - 9.6.6.1. UAE: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  - 9.6.6.2. UAE: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  - 9.6.6.3. UAE: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  - 9.6.6.4. UAE: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
- 9.6.7. Diabetes Drugs Market - Israel
  - 9.6.7.1. Israel: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  - 9.6.7.2. Israel: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  - 9.6.7.3. Israel: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  - 9.6.7.4. Israel: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
- 9.6.8. Diabetes Drugs Market - South Africa
  - 9.6.8.1. South Africa: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  - 9.6.8.2. South Africa: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  - 9.6.8.3. South Africa: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  - 9.6.8.4. South Africa: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
- 9.6.9. Diabetes Drugs Market - Rest of Middle East & Africa
  - 9.6.9.1. Rest of Middle East & Africa: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  - 9.6.9.2. Rest of Middle East & Africa: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  - 9.6.9.3. Rest of Middle East & Africa: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  - 9.6.9.4. Rest of Middle East & Africa: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
9.7. Diabetes Drugs Market - Latin America
- 9.7.1. Latin America: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
- 9.7.2. Latin America: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
- 9.7.3. Latin America: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
- 9.7.4. Latin America: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
- 9.7.5. Diabetes Drugs Market - Mexico
  - 9.7.5.1. Mexico: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  - 9.7.5.2. Mexico: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  - 9.7.5.3. Mexico: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  - 9.7.5.4. Mexico: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
- 9.7.6. Diabetes Drugs Market - Brazil
  - 9.7.6.1. Brazil: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  - 9.7.6.2. Brazil: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  - 9.7.6.3. Brazil: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  - 9.7.6.4. Brazil: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
- 9.7.7. Diabetes Drugs Market - Argentina
  - 9.7.7.1. Argentina: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  - 9.7.7.2. Argentina: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  - 9.7.7.3. Argentina: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  - 9.7.7.4. Argentina: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
- 9.7.8. Diabetes Drugs Market - Rest of Latin America
  - 9.7.8.1. Rest of Latin America: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  - 9.7.8.2. Rest of Latin America: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  - 9.7.8.3. Rest of Latin America: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  - 9.7.8.4. Rest of Latin America: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)

10. Competitive Landscape

10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

11.1. Novo Nordisk
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
11.2. Sanofi
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
11.3. Eli Lilly
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
11.4. Merck
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
11.5. Boehringer Ingelheim
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
11.6. AstraZeneca
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
11.7. Johnson & Johnson
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
11.8. Novartis
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
11.9. Bayer
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
11.10. GlaxoSmithKline
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development